For nearly two decades, carbonic anhydrase IX (CAIX) expression has been investigated as a prognostic marker in renal cell carcinoma (RCC). During this time, CAIX-directed treatments have emerged, including 177Lu-labelled girentuximab. A small phase II study highlights modest efficacy and a concerning safety profile associated with this compound in patients with metastatic RCC.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy
Molecular Cancer Open Access 14 October 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Muselaers, C. H. et al. Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. 69, 767–770 (2016).
Belldegrun, A. S. et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC — results and implications for adjuvant clinical trials [abstract]. J. Clin. Oncol. 31 (Suppl.), 4507 (2013).
Stillebroer, A. B. et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. 64, 478–485 (2013).
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814–1823 (2015).
Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482 (2015).
van Kuijk, S. J. et al. Prognostic significance of carbonic anhydrase IX expression in cancer patients: a meta-analysis. Front. Oncol. 6, 69 (2016).
Bui, M. H. T. et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802–811 (2003).
McDermott, D. F. et al. The high-dose aldesleukin “Select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 21, 561–568 (2015).
Stewart, G. D. et al. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur. Urol. 66, 956–963 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.K.P. receives honoraria from Astellas, Medivation and Novartis, and receives consulting fees from Astellas, Aveo, BMS, Exelixis, Genentech, GSK, Novartis and Pfizer. N.A. declares no competing interests.
Rights and permissions
About this article
Cite this article
Pal, S., Agarwal, N. Finding a niche for girentuximab in metastatic renal cell carcinoma. Nat Rev Urol 13, 442–443 (2016). https://doi.org/10.1038/nrurol.2016.115
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.115
This article is cited by
-
Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy
Molecular Cancer (2020)